Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

This strong performance led Novartis to upgrade its full-year 2024 guidance, with products like Kesimpta, Kisqali, and Cosentyx being key contributors to this growth. However, despite these ...

Novartis AG (NVS) reports a strong quarter with significant sales increases across key products and a record $6 billion in ...

Novartis hopes Kisqali will give Pfizer’s Ibrance (palbociclib) blockbuster a run for its money in first line HR+/HER2+ metastatic breast cancer. Although Pfizer beat Novartis to market with ...

Good morning and good afternoon, and welcome to the Novartis Q3 2024 Results Release ... talk about a bit more over the course of the call; Kisqali's FDA approval and CHMP positive opinion in ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...

Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter. Sales of ...

Kisqali’s (breast cancer ... up 50% on solid growth in the United States and Europe. Novartis received approval for Pluvicto's expanded manufacturing capacity at Millburn, NJ.